skynesher/E+ via Getty Images
- Lantheus Holdings (NASDAQ:LNTH) Thursday announced its acquisition of the global rights of Life Molecular Imaging’s RM2, targeting the gastrin-releasing peptide receptor, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair.
- This acquisition strengthens Lantheus’ (LNTH) presence in prostate cancer and expands its pipeline to include breast and other cancers.
- The agreement includes global rights to this radiotheranostic pair for an upfront payment of $35 million and potential regulatory milestone payments plus royalties.
- Life Molecular, a subsidiary of Life Healthcare Group, will complete the Phase 1/2a dose escalation study in collaboration with Lantheus (LNTH).
- Source: Press Release